Medifast, Inc. Hits 52-Week Low at $11.25 Amid Ongoing Struggles

Medifast, Inc., a microcap company in the miscellaneous industry, has reached a new 52-week low of USD 11.25 on November 4, 2025. This significant decline reflects a challenging year for the company, which has seen its stock price drop by 43.09% over the past year, contrasting sharply with the S&P 500's performance of 19.89% during the same period.
The company's financial metrics indicate ongoing difficulties, with a net profit of just USD 0.33 million, representing a staggering decline of 87.43%. Additionally, Medifast's operating cash flow has hit a low of USD 4.15 million, and net sales for the most recent quarter were recorded at USD 105.56 million, the lowest in recent history.

Despite these challenges, Medifast maintains a high return on equity of 1.12% and a low debt-to-equity ratio of -0.73. However, the company has reported negative results for the last 12 consecutive quarters, highlighting a consistent trend of underperformance. With a market capitalization of USD 152 million, Medifast continues to navigate a complex financial landscape as it seeks to stabilize its operations.